SAN DIEGO--(BUSINESS WIRE)-- Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the company will participate in two upcoming investor conferences in December.

2020 RBC Capital Markets Healthcare Private Company Conference
Format: Analyst-Led Fireside Chat
Date: Tuesday, December 15, 2020
Time: 9:20 a.m. ET / 6:20 a.m. PT

SVB Leerink Biopharma Private Company Connect
Format: One-on-one meetings
Date: December 15-17, 2020

About Pipeline Therapeutics

Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company’s lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability. The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis. For more information, please visit www.pipelinetherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005650/en/